Long-term antiseizure medication use in patients after meningioma resection: identifying predictors for successful weaning and failures
ConclusionsPreoperative seizures, modified STAMPE2 score of 3 –5, non-skull base tumor location, intratumoral calcifications, and Ki67 >  7% were significant risk factors for inability to achieve seizure freedom without ASMs. In addition, the modified STAMPE2 score successfully predicted increased seizure risk following meningioma resection for patients with a score of 3 or higher. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 24, 2023 Category: Cancer & Oncology Source Type: research

Telomere maintenance mechanism subtype reveals different immune activity in vestibular schwannoma
ConclusionThese results suggest that personalized drug therapy could be developed from the perspective of precision medicine for patients with relatively high telomerase activity and a high ALT-like group. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 21, 2023 Category: Cancer & Oncology Source Type: research

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma
ConclusionsPT2385 monotherapy had limited activity in first recurrent GBM. Drug exposure was variable. Signals of activity were observed in GBM patients with high systemic exposure and acidic lesions on CEST imaging. A second-generation HIF2 α inhibitor is being studied. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 21, 2023 Category: Cancer & Oncology Source Type: research

Impact of boost sequence in concurrent chemo-radiotherapy on newly diagnosed IDH-wildtype glioblastoma multiforme
ConclusionsThis study found no significant difference in OS between SEB and SIB for GBM patients treated with CCRT. Further research is needed to validate these findings and to determine the optimal boost techniques for this patient population. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 20, 2023 Category: Cancer & Oncology Source Type: research

Improved survival outcome with not-delayed radiotherapy and immediate PD-1/PD-L1 inhibitor for non-small-cell lung cancer patients with brain metastases
ConclusionsDelayed RT brought poor survival outcomes including iLPFS, iDPFS, and OS in NSCLC patients. The shorter interval of RT and ICI is associated with better BOR. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research

Glioblastomas at the white matter of temporo-parietal junction cause a poor postoperative independence level
ConclusionsGBMs involving the right WM-TPJ are more likely to result in poor postoperative KPS scores and prognoses. Impairments of several kinds of brain functions caused by tumor invasion to the WM-TPJ may be associated with lower KPS scores. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research

Single-fraction radiosurgery outcomes for large vestibular schwannomas in the upfront or post-surgical setting: a systematic review and International Stereotactic Radiosurgery Society (ISRS) Practice Guidelines
ConclusionsUpfront SRS resulted in high rates of tumor control with acceptable rates of facial palsy and hearing preservation as compared to the results in those series including patients with prior surgery (level C evidence). Therefore, although large VS are considered classic indication for microsurgical resection, upfront SRS can be considered in selected patients and we recommend a prescribed marginal dose from 11 to 13 Gy (level C evidence). (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 16, 2023 Category: Cancer & Oncology Source Type: research

Residual diffusion-weighted imaging hyperintense signal in primary central nervous system lymphoma can predict early recurrence
ConclusionA residual DWI hyperintense signal at the end of treatment was statistically associated with shorter PFS. Among patients who achieved CR/CRu evaluated based on postcontrast T1WI, DWI could be a valuable additional sequence to predict the early recurrence of PCNSL. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 13, 2023 Category: Cancer & Oncology Source Type: research

Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy
ConclusionsTNFAIP2 knockdown induces ICD by downregulating TNFAIP2 in GBM. In addition, TNFAIP2 knockdown sensitized glioma to anti-PD-1 therapy. Hence, targeting TNFAIP2 alone or in combination with anti-PD-1 therapy may be a potential strategy for GBM treatment through ICD. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 11, 2023 Category: Cancer & Oncology Source Type: research

Pachymeningeal disease: a systematic review and metanalysis
ConclusionWhile PMD has a superior prognosis to LMD, it is nevertheless a critical oncologic event associated with significant mortality and remains poorly recognized. PMD is predominantly observed in patients with controlled systemic disease status and infratentorial location. Future treatment strategies should focus on reducing surgical seeding and sterilizing surgical cavities. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 10, 2023 Category: Cancer & Oncology Source Type: research

Intraoperative or postoperative stereotactic radiotherapy for brain metastases: time to systemic treatment onset and other patient-relevant outcomes
ConclusionIORT for BMs results in faster completion of interdisciplinary treatment when compared to adjuvant SRT, without increasing corticosteroid intake or prolonging in-hospital times. A randomised phase III trial will determine the clinical effects of shorter TTNT. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 9, 2023 Category: Cancer & Oncology Source Type: research

Letter to the editor: the impact of systemic treatment on brain metastases should be considered in clinical outcome analysis
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 9, 2023 Category: Cancer & Oncology Source Type: research

Sexually dimorphic effect of H-ferritin genetic manipulation on survival and tumor microenvironment in a mouse model of glioblastoma
ConclusionGenetic manipulation ofFth1 which leads to reduced systemic levels of FTH1 protein had a sexually dimorphic impact on survival.Fth1 heterozygosity significantly worsened survival in females but did not affect survival in male GBMs. Furthermore, the genetic manipulation ofFth1 significantly affected tumor infiltration of T-cells, CD8  + T cells, fibroblasts, and mast cells in a sexually dimorphic manner. These results demonstrate a role for FTH1 and presumably iron status in establishing the tumor cellular landscape that ultimately impacts survival and further reveals a sex bias that may inform the population ...
Source: Journal of Neuro-Oncology - October 9, 2023 Category: Cancer & Oncology Source Type: research

Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors
ConclusionspPBTs commonly experience elevated symptoms of anxiety and depression that may fluctuate in clinically meaningful manners throughout the disease. Routine screening for elevated symptoms is needed to capture clinically meaningful changes and identify factors affecting symptoms to intervene on. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 7, 2023 Category: Cancer & Oncology Source Type: research

The impact of changes in gadolinium-enhancement on disease progression in children with neurofibromatosis type 1-associated optic pathway glioma: a retrospective analysis
ConclusionIncreased gadolinium-enhancement independent of a concurrent increase in tumor size on MRI should not be used as a marker of NF1-OPG progression and does not appear to be associated with visual decline or initiation of chemotherapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - October 7, 2023 Category: Cancer & Oncology Source Type: research